Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.83
JAZZ's Cash to Debt is ranked lower than
82% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. JAZZ: 0.83 )
Ranked among companies with meaningful Cash to Debt only.
JAZZ' s Cash to Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.85 Max: No Debt
Current: 0.83
Equity to Asset 0.46
JAZZ's Equity to Asset is ranked lower than
73% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. JAZZ: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
JAZZ' s Equity to Asset Range Over the Past 10 Years
Min: -0.84  Med: 0.40 Max: 0.87
Current: 0.46
-0.84
0.87
Interest Coverage 9.70
JAZZ's Interest Coverage is ranked lower than
80% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. JAZZ: 9.70 )
Ranked among companies with meaningful Interest Coverage only.
JAZZ' s Interest Coverage Range Over the Past 10 Years
Min: 0.7  Med: 8.93 Max: 76.32
Current: 9.7
0.7
76.32
F-Score: 8
Z-Score: 3.81
M-Score: -2.61
WACC vs ROIC
7.07%
20.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 37.93
JAZZ's Operating margin (%) is ranked higher than
94% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. JAZZ: 37.93 )
Ranked among companies with meaningful Operating margin (%) only.
JAZZ' s Operating margin (%) Range Over the Past 10 Years
Min: -252.34  Med: 24.97 Max: 46.95
Current: 37.93
-252.34
46.95
Net-margin (%) 24.64
JAZZ's Net-margin (%) is ranked higher than
91% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. JAZZ: 24.64 )
Ranked among companies with meaningful Net-margin (%) only.
JAZZ' s Net-margin (%) Range Over the Past 10 Years
Min: -273.04  Med: 11.92 Max: 49.25
Current: 24.64
-273.04
49.25
ROE (%) 22.13
JAZZ's ROE (%) is ranked higher than
94% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. JAZZ: 22.13 )
Ranked among companies with meaningful ROE (%) only.
JAZZ' s ROE (%) Range Over the Past 10 Years
Min: 4.38  Med: 22.19 Max: 111.92
Current: 22.13
4.38
111.92
ROA (%) 9.80
JAZZ's ROA (%) is ranked higher than
90% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. JAZZ: 9.80 )
Ranked among companies with meaningful ROA (%) only.
JAZZ' s ROA (%) Range Over the Past 10 Years
Min: -113.42  Med: 5.97 Max: 64.21
Current: 9.8
-113.42
64.21
ROC (Joel Greenblatt) (%) 313.90
JAZZ's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. JAZZ: 313.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
JAZZ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5278.54  Med: 583.84 Max: 11377.93
Current: 313.9
-5278.54
11377.93
Revenue Growth (3Y)(%) 29.20
JAZZ's Revenue Growth (3Y)(%) is ranked higher than
82% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. JAZZ: 29.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
JAZZ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.3  Med: 29.70 Max: 47.7
Current: 29.2
-2.3
47.7
EBITDA Growth (3Y)(%) 29.90
JAZZ's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. JAZZ: 29.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
JAZZ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.8  Med: 29.90 Max: 74.9
Current: 29.9
3.8
74.9
EPS Growth (3Y)(%) 6.40
JAZZ's EPS Growth (3Y)(%) is ranked higher than
64% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. JAZZ: 6.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
JAZZ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.4  Med: 4.40 Max: 61.7
Current: 6.4
-66.4
61.7
» JAZZ's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

JAZZ Guru Trades in Q2 2015

Jim Simons 18,300 sh (New)
NWQ Managers 126,680 sh (+95.42%)
Ken Fisher 1,300 sh (unchged)
Steve Mandel Sold Out
Pioneer Investments 322,324 sh (-0.19%)
RS Investment Management 212,193 sh (-15.28%)
Joel Greenblatt 3,565 sh (-67.22%)
» More
Q3 2015

JAZZ Guru Trades in Q3 2015

Paul Tudor Jones 5,531 sh (New)
Steven Cohen 21,915 sh (New)
Joel Greenblatt 25,672 sh (+620.11%)
Jim Simons 124,300 sh (+579.23%)
RS Investment Management 317,133 sh (+49.45%)
Ken Fisher 1,725 sh (+32.69%)
Pioneer Investments 334,648 sh (+3.82%)
NWQ Managers 123,720 sh (-2.34%)
» More
Q4 2015

JAZZ Guru Trades in Q4 2015

George Soros 3,200 sh (New)
Louis Moore Bacon 35,000 sh (New)
Joel Greenblatt 184,961 sh (+620.48%)
Paul Tudor Jones 6,788 sh (+22.73%)
RS Investment Management 359,125 sh (+13.24%)
Pioneer Investments 363,799 sh (+8.71%)
Ken Fisher 1,859 sh (+7.77%)
NWQ Managers Sold Out
Steven Cohen Sold Out
Jim Simons 18,800 sh (-84.88%)
» More
Q1 2016

JAZZ Guru Trades in Q1 2016

Steven Cohen 74,500 sh (New)
Lee Ainslie 9,070 sh (New)
Jim Simons 215,100 sh (+1044.15%)
Paul Tudor Jones 13,552 sh (+99.65%)
Pioneer Investments 462,460 sh (+27.12%)
Joel Greenblatt 197,619 sh (+6.84%)
Ken Fisher 1,949 sh (+4.84%)
Louis Moore Bacon Sold Out
George Soros Sold Out
RS Investment Management 356,361 sh (-0.77%)
» More
» Details

Insider Trades

Latest Guru Trades with JAZZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ALKS, OTCPK:GMXAY, NAS:MDVN, NAS:SGEN, NAS:ALNY, NAS:UTHR, OTCPK:SBMFF, NAS:ANAC, NAS:TSRO, NAS:ACAD, NAS:TECH, NAS:ICPT, OTCPK:BTGGF, NAS:IONS, NAS:JUNO, NAS:CBPO, NYSE:XON, OTCPK:SOLTF, NAS:LGND, NAS:KITE » details
Traded in other countries:J7Z.Germany,
Jazz Pharmaceuticals PLC is a specialty pharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs.

Jazz Pharmaceuticals PLC was originally incorporated in California in March 2003 and was reincorporated in Delaware in January 2004. The Company was originally formed as a private limited liability company in March 2005 under the name Azur Pharma Limited, and was subsequently re-registered as a public limited company under the name Azur Pharma Public Limited Company in October 2011. On January 18, 2012, the business of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in the Azur Merger in connection with which Azur Pharma was re-named Jazz Pharmaceuticals plc. It is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Its marketed products are: Xyrem, Erwinaze and Defitelio. Xyrem (sodium oxybate) oral solution, is a product approved by the U.S. Food and Drug Administration, or FDA, for the treatment of both cataplexy and excessive daytime sleepiness, or EDS, in patients with narcolepsy; Erwinaze (asparaginase Erwinia chrysanthemi) is a treatment approved in the U.S. and in certain markets in Europe (where it is marketed as Erwinase) for patients with acute lymphoblastic leukemia, or ALL, who have developed hypersensitivity to E. coli-derived asparaginase; and Defitelio (defibrotide) is a product approved in Europe for the treatment of severe hepatic veno-occlusive disease, or VOD, in adults and children undergoing hematopoietic stem cell transplantation, or HSCT, therapy. Its commercial operations are in the U.S. and Europe. In the U.S., Xyrem, is sold to one specialty pharmacy, Express Scripts, which ships Xyrem directly to patients. Erwinaze is sold to hospitals through a specialty distributor, McKesson Corporation. Prialt is sold in the U.S. through an exclusive pharmacy to other pharmacies and medical facilities, and other products are sold in the U.S. to distributors who distribute the product to pharmacies and hospitals. Its patents include Xyrem, Defitelio, amd Erwinaze. The manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, sale, distribution, record keeping, importing and exporting of products and research and development activities are subject to extensive regulation by the FDA, the EC the competent authorities of the EU member states and other regulatory authorities.

Top Ranked Articles about Jazz Pharmaceuticals PLC

Stocks Fisher Investments Has Bought for Past 2 Quarters Fisher adds to stake in Colgate and Energizer
Ken Fisher (Trades, Portfolio) is the CEO and CIO of Fisher Investments. The investment philosophy at Fisher Investments is based on the idea that supply and demand of securities is the sole determinate of pricing. The following are the companies the investor has been buying for at least the last two quarters. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.61
JAZZ's P/E(ttm) is ranked higher than
56% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.09 vs. JAZZ: 26.61 )
Ranked among companies with meaningful P/E(ttm) only.
JAZZ' s P/E(ttm) Range Over the Past 10 Years
Min: 10.62  Med: 26.13 Max: 99999999.99
Current: 26.61
10.62
99999999.99
Forward P/E 12.79
JAZZ's Forward P/E is ranked higher than
75% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 21.32 vs. JAZZ: 12.79 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.61
JAZZ's PE(NRI) is ranked higher than
57% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 29.71 vs. JAZZ: 26.61 )
Ranked among companies with meaningful PE(NRI) only.
JAZZ' s PE(NRI) Range Over the Past 10 Years
Min: 11.75  Med: 26.13 Max: 99999999.99
Current: 26.61
11.75
99999999.99
Price/Owner Earnings (ttm) 26.59
JAZZ's Price/Owner Earnings (ttm) is ranked higher than
59% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 34.88 vs. JAZZ: 26.59 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
JAZZ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.91  Med: 25.59 Max: 432.91
Current: 26.59
8.91
432.91
P/B 5.31
JAZZ's P/B is ranked lower than
69% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. JAZZ: 5.31 )
Ranked among companies with meaningful P/B only.
JAZZ' s P/B Range Over the Past 10 Years
Min: 2.46  Med: 6.04 Max: 32
Current: 5.31
2.46
32
P/S 6.57
JAZZ's P/S is ranked higher than
67% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. JAZZ: 6.57 )
Ranked among companies with meaningful P/S only.
JAZZ' s P/S Range Over the Past 10 Years
Min: 0.21  Med: 5.90 Max: 12
Current: 6.57
0.21
12
PFCF 16.25
JAZZ's PFCF is ranked higher than
67% of the 147 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. JAZZ: 16.25 )
Ranked among companies with meaningful PFCF only.
JAZZ' s PFCF Range Over the Past 10 Years
Min: 11.77  Med: 17.36 Max: 91.05
Current: 16.25
11.77
91.05
POCF 15.34
JAZZ's POCF is ranked higher than
63% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 22.90 vs. JAZZ: 15.34 )
Ranked among companies with meaningful POCF only.
JAZZ' s POCF Range Over the Past 10 Years
Min: 9.59  Med: 16.35 Max: 55.21
Current: 15.34
9.59
55.21
EV-to-EBIT 17.08
JAZZ's EV-to-EBIT is ranked higher than
55% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. JAZZ: 17.08 )
Ranked among companies with meaningful EV-to-EBIT only.
JAZZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.5  Med: 16.45 Max: 74.1
Current: 17.08
-8.5
74.1
EV-to-EBITDA 14.15
JAZZ's EV-to-EBITDA is ranked higher than
57% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. JAZZ: 14.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
JAZZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.9  Med: 13.50 Max: 42.2
Current: 14.15
-10.9
42.2
PEG 0.73
JAZZ's PEG is ranked higher than
84% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. JAZZ: 0.73 )
Ranked among companies with meaningful PEG only.
JAZZ' s PEG Range Over the Past 10 Years
Min: 0.61  Med: 1.05 Max: 8.83
Current: 0.73
0.61
8.83
Current Ratio 3.19
JAZZ's Current Ratio is ranked lower than
62% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. JAZZ: 3.19 )
Ranked among companies with meaningful Current Ratio only.
JAZZ' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 2.66 Max: 5.55
Current: 3.19
0.2
5.55
Quick Ratio 3.12
JAZZ's Quick Ratio is ranked lower than
59% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. JAZZ: 3.12 )
Ranked among companies with meaningful Quick Ratio only.
JAZZ' s Quick Ratio Range Over the Past 10 Years
Min: 0.17  Med: 2.57 Max: 5.46
Current: 3.12
0.17
5.46
Days Inventory 101.88
JAZZ's Days Inventory is ranked higher than
60% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. JAZZ: 101.88 )
Ranked among companies with meaningful Days Inventory only.
JAZZ' s Days Inventory Range Over the Past 10 Years
Min: 70.82  Med: 103.00 Max: 164.69
Current: 101.88
70.82
164.69
Days Sales Outstanding 60.44
JAZZ's Days Sales Outstanding is ranked higher than
52% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. JAZZ: 60.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
JAZZ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.12  Med: 46.23 Max: 58
Current: 60.44
30.12
58
Days Payable 121.91
JAZZ's Days Payable is ranked higher than
72% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. JAZZ: 121.91 )
Ranked among companies with meaningful Days Payable only.
JAZZ' s Days Payable Range Over the Past 10 Years
Min: 73.94  Med: 81.91 Max: 285.12
Current: 121.91
73.94
285.12

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.78
JAZZ's Price/Projected FCF is ranked higher than
74% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 3.44 vs. JAZZ: 1.78 )
Ranked among companies with meaningful Price/Projected FCF only.
JAZZ' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.64  Med: 3.23 Max: 55.99
Current: 1.78
1.64
55.99
Price/Median PS Value 1.12
JAZZ's Price/Median PS Value is ranked lower than
62% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. JAZZ: 1.12 )
Ranked among companies with meaningful Price/Median PS Value only.
JAZZ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.98 Max: 1.55
Current: 1.12
0.05
1.55
Price/Peter Lynch Fair Value 1.08
JAZZ's Price/Peter Lynch Fair Value is ranked higher than
71% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.76 vs. JAZZ: 1.08 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JAZZ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.99  Med: 1.43 Max: 14.94
Current: 1.08
0.99
14.94
Earnings Yield (Greenblatt) (%) 5.84
JAZZ's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. JAZZ: 5.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JAZZ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.3  Med: 5.60 Max: 10.7
Current: 5.84
1.3
10.7
Forward Rate of Return (Yacktman) (%) 36.89
JAZZ's Forward Rate of Return (Yacktman) (%) is ranked higher than
88% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.20 vs. JAZZ: 36.89 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JAZZ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -43.1  Med: 1.50 Max: 49.5
Current: 36.89
-43.1
49.5

More Statistics

Revenue (TTM) (Mil) $1,352
EPS (TTM) $ 5.30
Beta0.97
Short Percentage of Float3.27%
52-Week Range $108.50 - 194.73
Shares Outstanding (Mil)60.42

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 1,520 1,750 1,975
EPS ($) 10.82 12.45 14.89
EPS w/o NRI ($) 10.82 12.45 14.89
EPS Growth Rate
(3Y to 5Y Estimate)
10.49%
Dividends Per Share ($)
» More Articles for JAZZ

Headlines

Articles On GuruFocus.com
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
Stocks Fisher Investments Has Bought for Past 2 Quarters May 03 2016 
Citigroup, Amgen Are Trading With Wide Margin of Safety Mar 30 2016 
Weekly Insider Sells Highlight: MHK, JAZZ, BMY, ZAYO Mar 23 2015 
Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
Growth Momentum Should Continue For This Pharmaceutical Company Nov 15 2014 
Jazz Pharmaceuticals: Growth Trajectory Can Continue In Future Sep 03 2014 
Weekly CFO Sells Highlight: Google Inc, Jazz Pharmaceuticals PLC, Jack in the Box Inc. Jun 30 2014 
Weekly Insider Sells Highlight: JAZZ, HD, ESRX, SCI Mar 11 2014 
Weekly CFO Sells Highlight: Jazz Pharmaceuticals PLC, Carnival PLC, Juniper Networks Inc., Home Depo Mar 10 2014 

More From Other Websites
What Is An Options Sweep? Jul 22 2016
Bulls Crowd Into Jazz Pharmaceuticals For Good Reason Jul 15 2016
Jazz Pharmaceuticals: How Much Return Potential Does It Have? Jul 15 2016
A Look at Celator’s Lead Drug Vyxeos Jul 14 2016
How Can Celator’s Portfolio Complement Jazz Pharmaceuticals? Jul 14 2016
A Look at Jazz Pharmaceuticals’ Celator Acquisition Deal Jul 13 2016
Why Did Jazz Fall after Celator Acquisition Announcement? Jul 13 2016
JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Jul 12 2016
Jazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares... Jul 12 2016
Jazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares... Jul 12 2016
Jazz Pharma (JAZZ) Stock Receives 'Outperform' Rating at BMO Capital Jun 29 2016
Jazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator... Jun 26 2016
Jazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator... Jun 26 2016
Five companies that could buy Ariad this year for as much as $2.9B Jun 23 2016
Jazz Pharmaceuticals PLC Conference Call to Discuss On JZP-110 Investor Update scheduled for 4:30 pm... Jun 20 2016
Jazz Pharmaceuticals Plc – Value Analysis (NASDAQ:JAZZ) : June 20, 2016 Jun 20 2016
Jazz Pharmaceuticals Offers HAL Study Data on JZP-110 Jun 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)